The sponsor of a clinical trial is an individual, company, institution, or organisation that assumes responsibility for initiating, managing, and financing a clinical study. The sponsor’s role is comprehensively regulated in the ICH guideline E6(R3) on Good Clinical Practice as well as in EU Regulation No. 536/2014 (CTR). The sponsor is the central accountable entity throughout the entire lifecycle of a clinical trial—from planning and conduct through to archiving.
Sponsor responsibilities
The sponsor bears overall responsibility for the quality and integrity of the clinical trial. Key responsibilities include drafting and approving the protocol, selecting qualified investigators (Principal Investigators) and trial sites, and submitting the clinical trial application to the competent authorities and ethics committees. The sponsor is responsible for implementing a quality management system in accordance with ICH E6(R3), including risk management, study monitoring, and ensuring data integrity within clinical data management.
In addition, the sponsor is responsible for pharmacovigilance during clinical development. The sponsor must report suspected unexpected serious adverse reactions (SUSARs) to the authorities and ethics committees within the required timelines and submit the annual Development Safety Update Report (DSUR). Complete archiving of all study-relevant documentation in the Trial Master File (TMF) is also one of the sponsor’s core obligations.
Delegation to CROs
The sponsor may delegate tasks and functions to Contract Research Organisations (CROs). Delegation must be agreed in writing and clearly define the specific tasks, responsibilities, and interfaces. Despite delegation, overall responsibility for the quality and integrity of the trial remains with the sponsor. The sponsor must ensure that the CRO has sufficient qualifications, capacity, and quality systems. As part of oversight activities, the sponsor monitors the CRO’s performance and conducts regular audits.
The sponsor’s responsibility does not end with the last patient visit: preparing the Clinical Study Report (CSR) in accordance with ICH E3 and archiving the Trial Master File for at least 25 years after study completion are further essential obligations. When submitting the marketing authorisation application, the sponsor is responsible for the completeness and quality of the entire dossier, including the integrity of all clinical data.
Sponsor-Investigator
A sponsor-investigator is an individual who acts both as sponsor and as Principal Investigator—typically in academically initiated, non-commercial studies (Investigator-Initiated Trials, IITs). In this case, the individual assumes all obligations of both roles. EU Regulation 536/2014 enables academics and research institutions to conduct clinical trials as sponsor-investigators, provided they meet the regulatory requirements. In some Member States, reduced requirements apply to non-commercial sponsors.
Sponsor responsibilities in multicentre studies
In multicentre studies, the sponsor coordinates all trial sites and ensures consistent implementation of the protocol. Where applicable, the sponsor appoints a Coordinating Investigator who assumes scientific coordination between sites. Regulatory submission is made centrally via the EMA’s Clinical Trials Information System (CTIS) for studies in the EU. The sponsor is responsible for communication with all national competent authorities and ethics committees, as well as for coordinating protocol amendments and safety reporting across all sites.
Quality assurance in multicentre studies places particular demands on the sponsor’s oversight system. Risk-based monitoring strategies, explicitly promoted by ICH E6(R3), enable differentiated allocation of resources: sites with a higher risk profile receive more intensive support, while well-performing sites can operate with reduced monitoring effort. Central statistical data monitoring complements on-site monitoring and enables early detection of data anomalies across all sites. The sponsor is also responsible for conducting sponsor audits to verify the compliance of the CRO and trial sites with the protocol and GCP requirements. Audit findings feed into risk management and the adjustment of the monitoring strategy.
Frequently Asked Questions
What is the difference between a sponsor and a marketing authorisation holder?
The sponsor is responsible for conducting clinical trials, whereas the marketing authorisation holder (MAH) is responsible for an authorised medicinal product on the market. Often, the same pharmaceutical company is both the sponsor of clinical development and later the MAH. After authorisation, the sponsor’s pharmacovigilance obligations transfer to the MAH’s obligations.
Which documents must the sponsor retain in the Trial Master File?
The TMF contains all essential documents that demonstrate the conduct of the study in accordance with GCP, applicable regulations, and the protocol. These include, among others, the protocol and amendments, Investigator’s Brochure, ethics approvals, regulatory authorisations, monitoring reports, SAE reports, laboratory reports, randomisation lists, and correspondence. The ICH E6(R3) guideline defines the minimum requirements for TMF content. In the EU, the archiving obligation applies for at least 25 years after completion of the study.
What happens if a sponsor does not fulfil its obligations?
In the event of breaches of GCP requirements, authorities such as the EMA, BfArM, or national inspection authorities may impose sanctions. These range from conditions and corrective actions to rejection of marketing authorisation applications, and from trial suspensions to terminations. Serious GCP violations may lead regulatory inspections to deem the study data unusable, which can have significant implications for the entire development programme.
Regulatory References
- ICH E6(R3): Good Clinical Practice – Section 5: Sponsor
- EU Regulation No. 536/2014 (CTR), Articles 71–78: Sponsor responsibilities
- German Medicines Act (AMG) Sections 40–42a: Requirements for sponsors of clinical trials in Germany
- EMA GCP Inspection Findings: Sponsor Responsibilities – Common Deficiencies
- ICH E8(R1): General Considerations for Clinical Studies